Search for: "RANBAXY INC" Results 41 - 60 of 93
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Jun 2013, 9:36 pm by Jason Rantanen
In Australia the patentability of such materials has recently been confirmed by the Federal Court of Australia in Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65 (15 February 2013)[3], see Vaughn Barlow, CIPA, March 2013, 122-123. [read post]
21 May 2013, 2:26 pm by Fraud Fighters
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
14 May 2013, 10:50 am
Ranbaxy USA Inc., the American subsidiary of Ranbaxy Laboratories Limited, an Indian generic pharmaceutical maker, has agreed to pay $500 million to settle fines related to claims that it made false statements to the FDA about its manufacturing practices abroad and sold substandard medications and pay penalties. [read post]
11 Feb 2013, 6:44 pm by FDABlog HPM
District Court for the District of Columbia ruled against FDA in a challenge brought by Watson Laboratories, Inc. [read post]
18 Jan 2013, 2:06 pm by Bexis
  The Decherts are too involved in this litigation to comment publicly.There aren’t many research-oriented pharmaceutical companies based in Alabama, and after last week’s execrable decision in Wyeth, Inc. v. [read post]
2 Jan 2013, 6:50 pm by FDABlog HPM
District Court for the District of Columbia granted both FDA’s and Intervenor-Defendant Ranbaxy Laboratories Limited’s (“Ranbaxy’s”) Motions for Summary Judgment and denied Mylan Laboratories Limited’s and Mylan Pharmaceuticals Inc. [read post]
13 Dec 2012, 9:44 am by Rajiv Kr. Choudhry
Patil 3715/DELNP/2007 ENDORECHERCHE, INC Granted Dr.Rajesh Dixit 7676/DELNP/2006 GENENTECH, INC. [read post]
1 Dec 2012, 8:00 pm by Lawrence B. Ebert
Separately, as to Ranbaxy's version of Lipitor ( atorvastatin ), note text from BusinessWeek in the postDrugmaker Ranbaxy halts generic Lipitor production : Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were recalled in November. [read post]
27 Nov 2012, 2:57 am by Robert Kraft
(RBXY) fell the most in more than three months after announcing a recall of the company’s generic version of Pfizer Inc. [read post]
23 Nov 2012, 10:40 am
Indian drugmaker Ranbaxy Laboratories said it issued the recall because of its generic version of Pfizer Inc.' [read post]
22 Nov 2012, 2:44 pm by Howard Knopf
It didn't take long after the SCC's decision of November 8, 2012  for the generic drug companies to get their Notices of Compliance for SILDENAFIL CITRATE  to compete with Pfizer's popular brand name drug VIAGRA.Here's the current list of approved manufacturers: APO-SILDENAFIL Manufacturer: APOTEX INCORPORATED NOC Date: 2012-11-16 Medicinal Ingredients: … [read post]
1 Nov 2012, 6:50 pm by FDABlog HPM
District Court for the District of Columbia in which Mylan Laboratories Limited and Mylan Pharmaceuticals Inc. are challenging FDA’s decision that Ranbaxy Inc. is eligible for 180-day exclusivity for its generic versions of DIOVAN (valsartan) Tablets (see our previous post here) got us thinking about the instances in which FDA determined that 180-day exclusivity was not forfeited under FDC Act § 505(j)(5)(D)(i)(IV) because of some “extenuating circumstance.”  [read post]
29 Aug 2012, 3:15 am by Lawrence B. Ebert
Ranbaxy Pharmaceuticals, Inc., 336 F.3d 1322, 1330 (Fed. [read post]